Manufacturing Agreement with SAFC for Lead anticancer agent Cloretazine® (VNP40101M), Extended by Vion Pharmaceuticals
Vion Pharmaceuticals, Inc. (Nasdaq: VION) has recently extended its manufacturing agreement with SAFC (a member of the Sigma-Aldrich Group) for its lead anticancer agent Cloretazine® (VNP40101M).
The extended agreement will allow SAFC to continue the manufacture of Cloretazine® (VNP40101M) active pharmaceutical ingredient (API) to September 2009.
SAFC is the custom manufacturing group within the Sigma-Aldrich Group focused on both biochemical production and the manufacturing of complex, multi-step organic synthesis of APIs and key intermediates.
Vion Pharmaceuticals is committed to developing and commercializing innovative cancer therapeutics.
Find more details from the press release (a pdf file).
Comment Preview